NL-OMON55929招募中不适用
Assessing the optimal amount of tissue sampling in contrast-enhanced biopsy - CESB
Zuyderland Medisch Centrum0 个研究点目标入组 150 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Included women are older than 18 years of age, with a recent finding on CEM
- •requiring CESB (a so-called 'recombined image only lesion' or ROL). Only women
- •able to provide written informed consent will be considered for this study.
排除标准
- •Excluded are all men (male sex), and women (female sex) who are
- •contra-indicated for CESB (for example, with impaired renal function or known
- •hypersensitivity reactions to iodinated contrast). Also excluded are pregnant
研究者
相似试验
尚未招募
不适用
Minimally invasive brain tissue sampling in determining the cause of death in stillbirths and neonates due to neurological insultsCTRI/2019/07/019979Research Triangle Institute RTI
招募中
不适用
A prospective study on comprehensive sampling to search exacerbation factors and efficacy predictors in patients with autoimmune and immune related diseasePatients with autoimmune/immune-related diseases such as ulcerative colitis, Crohn's disease, Bechet disease, immune-check point inhibitor related colitisJPRN-UMIN000041268Sapporo Medical University School of Medicine100
已完成
不适用
Development of an optimal sampling strategy for clozapine to predict area under the concentration-time curve ratios and the clinical validation of the dried blood spot analysis for clozapine10039628schizophreniaNL-OMON40128niversitair Medisch Centrum Groningen15
尚未招募
不适用
Removing a group of lymph nodes in axilla to stage the nodal involvement following chemotherapy in carcinoma breastCTRI/2020/09/028016INSTITUTIONAL SPONSORRCCTRIVANDRUM
已完成
不适用
Sample collection for an assay development to determine HSV-specific T-cell responses in blood samples from HSV-2 infected individuals and HSV-1 + HSV-2 infected individualsgenital herpesoral herpesB00Herpesviral [herpes simplex] infectionsDRKS00031143Heidelberg ImmunoTherapeutics GmbH29